Medical Advocates

   Medical Advocates for Social Justice

Kaletra Library Service 
 Conference Abstracts and Posters

• POSTER
  Cost-effectiveness of lopinavir/r tablets compared to atazanavir + ritonavir in antiretroviral experienced
  patients in the UK, Spain, Italy, and France based on results from BMS AI424-045
  KN Simpson, W Jones, R Rajagopalan, B Dietz
  PDF Poster    Abstract
• A WEEK-IN-REVIEW FEATURED REPORT
  POSTER
  Efficacy and safety of lopinavir/r and atazanavir without a nucleoside backbone in
  antiretroviral therapy experienced HIV-infected subjects
  DA Parks, HC Jennings, CW Taylor, et al
  PDF Poster    Abstract
• A WEEK-IN-REVIEW FEATURED REPORT
  POSTER
  Tolerability and preference of lopinavir/ritonavir (Kaletra) capsules versus tablets as
  single agent therapy (IMANI-2)
  J Gathe, B Lipman, B Miguel, et al
  PDF Poster    Abstract
• POSTER
  Lack of sex differences in once-daily lopinavir/ritonavir (LPV/r) pharmacokinetic (PK
  I Ofotokun, S Chuck, M Palau, et al
  PDF Poster   Abstract
• POSTER
  Significant improvements in self-reported gastrointestinal (GI) tolerability, quality of life
  (QoL), patient satisfaction, and adherence with lopinavir/ritonavir (LPV/r) after switching
  from BID soft-gel capsule (SGC) to BID tablets (TAB)
  S Schrader, SK Chuck, LW Rahn, et al
  PDF Poster  Abstract
• POSTER
  Improvements in self-reported adherence & gastrointestinal adverse effects (AEs) with
  lopinavir/ritonavir (LPV/r) after switching from soft-gel capsule (SGC) to tablet (TAB) varies
  by ethnicity
  S Schrader, SK Chuck, LW Rahn, et al
  PDF Poster  Abstract

• POSTER
  Relationship Between Time to Viral Load Suppression and First Month Adherence to Prescribed
  Antiretroviral Therapy
  RA Rode, BC Vrijens, AC Lange, et al
  PDF Poster   Abstract

• A WEEK-IN-REVIEW FEATURED REPORT
  POSTER
  Lipid-profile of lopinavir/ritonavir (LPV/r) in an 18-month French observational prospective cohort
  (Kaleobs cohort)
  M Dupon, J-Mi Livrozet, L Morand-Joubert, et al
  PDF Poster   Abstract

• A WEEK-IN-REVIEW FEATURED REPORT
  POSTER
  Efficacy of lopinavir/ritonavir (LPV/r) in clinical practice: an 18-month observational prospective
  cohort of 1315 patients (Kaleobs cohort
  J-M Livrozet, M Dupon, L Morand-Joubert, et al
  PDF Poster  Abstract
• A WEEK-IN-REVIEW FEATURED REPORT
  POSTER
  Impact of a lopinavir/ritonavir (LPV/r) monotherapy on self-reported side effects and global
  health perception among antiretroviral-naive patients: 48-week analysis of the MONARK Trial
  B Spire, F Marcellin, IC Codar, et al
  PDF Poster  Abstract
• POSTER
  Predicted pharmacokinetics of lopinavir after multiple dose administration of lopinavir/
  ritonavir tablet to pediatric patients
  W Liu, CE Klein, KC Marsh, et al
  PDF Poster  Abstract
• POSTER
  Pharmacokinetics of lopinavir and ritonavir after multiple dose administration of lopinavir/
  ritonavir tablet co-administered with efavirenz
  CE Klein, Y Cai, Y-L Chiu, et al
  PDF Poster   Abstract
• POSTER
  Gastrointestinal Complaints and use of Acid Reducing Agents are frequent in patients treated with
  Antiretrovirals
  E Toma , N Ackad , S Auger , J Sampalis
  PDF Poster     Abstract
• P-glycoprotein is inhibited by lopinavir and low-dose ritonavir in HIV-infected patients and in healthy
  men
  C Wyen, G Fatkenheuer, R Aarnoutse. et al
  Abstract
• Triglycerides and small, dense low-density lipoprotein in HIV infected patients treated with
  lopinavir/ritonavir as a component of the first combination antiretroviral therapy
  L Magenta, W O Richter, M Opravil, et al
  Abstract
• Second line lopinavir/ritonavir containing therapy is effective without major side effects after failing
  first line NNRTI containing regimens: 12 months follow-up study at Mulago Hospital Adult Infectious
  Diseases Clinic
  Ba Castelnuovo, F Lutwama, PMwebase, et al
  Abstract
• Plasma lopinavir levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and
  lamivudine
  K Manavi, A McDonald, Al Al-Sharqui
  Abstract
• Lipids and lipoproteins in HIV-subjects treated with lopinavir/ritonavir (L) or atazanavir/ritonavir
  (A) based antiretroviral therapy
  A Trein, E Schnaitmann, W O Richter
  Abstract
• Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz
  concentrations
  L Else, L Dickinson, M Schellenberger, et al
  Abstract
• Placental transfer of lopinavir, saquinavir, and ritonavir
  K Weizsaecker, C Feiterna, JP Siedentopf, et al
  Abstract
• The assessment of multi-locus gene effects upon lopinavir pharmacokinetics
  A Owen, T Mahungu, C Cook, et al
  Abstract
• Different rates of early viral load reduction with nevirapine or lopinavir/ritonavir-based combination
  antiretroviral therapies in pregnant women
  C Bell, N Desmond, GP Taylor
  Abstract
• Safety assessment of lopinavir/ritonavir (LPV/r) in HIV+ and hepatitis C (HCV) co-infected
  patients
  P Cote, C Cooper, JG Baril, et al
  Abstract
• Crossover, steady-state comparison of lopinavir/ritonavir (LPV/r) pharmacokinetics (PK) in women
  of colour
  IR McNicholl, PGerman, D Cohan, et al
  Abstract
• Failure of lopinavir/ritonavir-containing regimen with newly selected PI resistance mutations in an
  antiretroviral nave patient
  S Koch, A Kroidl, M Oette, et al
  Abstract
• Low incidence of severe liver events (SLE) in HIV patients with and without hepatitis C or B
  coinfection receiving lopinavir/ritonavir (LPV/r)
  I Aguilar, S Vergara, A Rivero,  et al
  Abstract
• Tolerability of lopinavir/ritonavir (LPV/r) liquid in HIV+ adults switched from the soft gelatin capsule
  (SGC)
  J Toy, M Harris, J da Silva, et al
  Abstract
• Similar virologic and immunologic response to efavirenz or lopinavir/ritonavir-based HAART in a large
  cohort ofantiretroviral-naïve patients with advanced HIV infection
  F Pulido, J Arribas, S Moreno, et al
  Abstract
• Long-term follow-up of IMANI I: pilot study of the safety and efficacy of lopinavir/ritonavir (LPV/r) as
  single agent therapy (SAT) in HIV-1 antiretroviral (ARV)-nave patients
  J  Gathe, Jr., C Mayberry, B Miguel, et al
  Abstract
• A study on the performance of combination of Kaletra and saquinavir twice-daily regimen on a group
  of antiretroviral therapy experienced patients
  K Manavi, C Burns, A McMillan
  Abstract